Cited by 164PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index.

PARP Inhibitors in Ovarian Cancer

Open access

Mittica, Gloria, Ghisoni, Eleonora, Giannone, Gaia, Genta, Sofia, Aglietta, Massimo, Sapino, Anna, Valabrega, Giorgio·2018·Recent Patents on Anti-Cancer Drug Discovery

DOI 10.2174/1574892813666180305165256

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients. OBJECTIVES: The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis. METHODS: We performed a review on Pubmed using 'ovarian cancer' and the name of each PARPi (PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The same search was performed on "clinicaltrial.gov" to identify ongoing clinical trials and on "google. com/patents" and "uspto.gov" for recent patents exploring PARPIs in ovarian cancer. RESULTS: Olaparib, Niraparib and Rucaparib are already approved for the treatment of recurrent EOC and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, but currently under investigation in early phase trials. Several studies are evaluating PARPis in monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-sensitive and resistant disease). CONCLUSION: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.

Integrity signals

Registry

Crossref · 10.2174/1574892813666180305165256

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276

Show all 100 references

Sorted by citations

Discovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y.-H., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 313
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma
Zhao, Y., Cao, J., Melamed, A., Worley, M. J., Gockley, A. A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 265
Exploiting DNA repair defects in colorectal cancer
Reilly, N. M., Novara, L., Nicolantonio, F. D., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 132
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Cecere, S. C., Giannone, G., Salutari, V., Arenare, L., Lorusso, D., Ronzino, G., Lauria, R., Cormio, G., Carella, C., Scollo, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.023 · Cited by 108
Self-citation
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
Borella, F., Ghisoni, E., Giannone, G., Cosma, S. D., Benedetto, C., Valabrega, G., & Katsaros, D. (2020) · Diagnostics · doi:10.3390/diagnostics10030146 · Cited by 95
Self-citation
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
Valabrega, G., Scotto, G., Tuninetti, V., Pani, A., & Scaglione, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084203 · Cited by 93
Self-citation
Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
Césaire, M., Thariat, J., Candéias, S. M., Stefan, D., Saintigny, Y., & Chevalier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123793 · Cited by 85
The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
Xu, S., & Tang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745187 · Cited by 87
Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
Li, Y., Gao, Y., Zhang, X., Guo, H., & Gao, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119986 · Cited by 68
Recent advancements of antiangiogenic combination therapies in ovarian cancer
An, D., Banerjee, S. N., & Lee, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102224 · Cited by 70
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis
Borella, F., Bertero, L., Morrone, A., Gambella, A., Bovetti, M., Cosma, S. D., Carosso, A. R., Katsaros, D., Gemmiti, S., Preti, M., et al. (2020) · Cancers · doi:10.3390/cancers12082156 · Cited by 55
Self-citation
IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer
Bley, N., Schott, A., Müller, S., Misiak, D., Lederer, M., Fuchs, T., Aßmann, C., Glaß, M., Ihling, C. H., Sinz, A., et al. (2020) · RNA Biology · doi:10.1080/15476286.2020.1812894 · Cited by 51
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
Li, Y., Wang, Y., Zhang, W., Wang, X., Chen, L., & Wang, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82990-y · Cited by 46
Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents
Ofori, S., & Awuah, S. G. (2019) · ACS Omega · doi:10.1021/acsomega.9b01106 · Cited by 41
Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine
Nilov, D. K., Maluchenko, N. V., Kurgina, T. A., Pushkarev, S. V., Lys, A., Kutuzov, M. M., Gerasimova, N. S., Feofanov, A. V., Švedas, V. K., Lavrik, O. I., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062159 · Cited by 36
The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing
Tao, M., & Wu, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02139-7 · Cited by 35
Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR
Young, R. J., França, P. D. D. S., Pirovano, G., Piotrowski, A. F., Nicklin, P. J., Riedl, C. C., Schwartz, J., Bale, T., Donabedian, P. L., Kossatz, S., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa119 · Cited by 35
DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
Sheng, X., Wang, J., Guo, Y. F., Zhang, J., & Luo, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.616098 · Cited by 35
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
Han, Y., Chen, M., Wang, H.-L., Hsu, J. L., Li, C.-W., Chu, Y., Liu, C., Nie, L., Chan, L.-C., Yam, C., et al. (2019) · Europe PMC (PubMed Central) · Cited by 33
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers
Putri, J. F., Bhargava, P., Dhanjal, J. K., Yaguchi, T., Sundar, D., Kaul, S. C., & Wadhwa, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1500-9 · Cited by 33
Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S.-B., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · BMC Cancer · doi:10.1186/s12885-020-07695-3 · Cited by 30
Molecular mechanisms of cisplatin resistance in ovarian cancer
Jiang, C., Shen, C., Ni, M., Huang, L., Hu, H., Dai, Q. Y., Zhao, H., & Zhu, Z. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.032 · Cited by 33
Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
Milanesio, M. C., Giordano, S., & Valabrega, G. (2020) · Cancers · doi:10.3390/cancers12051315 · Cited by 26
Self-citation
Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins
Manasaryan, G., Suplatov, D. A., Pushkarev, S. V., Drobot, V., Kuimov, A. N., Švedas, V. K., & Nilov, D. K. (2021) · Cancers · doi:10.3390/cancers13061201 · Cited by 27
Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
Pagkali, A., Mamais, I., Michalinos, A., & Agouridis, A. P. (2022) · Current Oncology · doi:10.3390/curroncol29010029 · Cited by 26
CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer
Xue, Y., Yin, T., Yuan, S., Wang, L., Lin, H., Jin, T., Xu, R., Gu, J., Shen, S., Chen, X., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101151 · Cited by 25
PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
Hsu, W.-J., Chen, C., Chang, Y., Cheng, C., Tsai, Y.-H., & Lin, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101009 · Cited by 25
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
Singh, N., Pay, S. L., Bhandare, S. B., Arimpur, U., & Motea, E. A. (2020) · Cancers · doi:10.3390/cancers12040972 · Cited by 24
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer
Sauriol, S. A., Carmona, E., Udaskin, M. L., Radulovich, N., Leclerc-Desaulniers, K., Rottapel, R. K., Oza, A. M., Lheureux, S., Provencher, D. M., & Mes‐Masson, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-30081-5 · Cited by 24
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options
Labrie, M., Kim, T., Ju, Z., Lee, S., Zhao, W., Fang, Y., Lu, Y., Chen, K., Ramirez, P. T., Frumovitz, M., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26947 · Cited by 24
Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
Huang, X., Li, X., Shan, W., Chen, Y., Zhu, Q., & Xia, B.-R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1131342 · Cited by 23
Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC)
Umar, H., Wahab, H. A., Attiq, A., Amjad, M. W., Bukhari, S. N. A., & Ahmad, W. (2024) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2024.111856 · Cited by 22
High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Deng, Y., Liu, L., Feng, W., Lin, Z., Ning, Y., & Luo, X. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574891x16666210706153740 · Cited by 21
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
Liao, M., Beltman, J., Giordano, H., Harding, T. C., Maloney, L., Simmons, A. D., & Xiao, J. J. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01157-8 · Cited by 20
BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis
Feng, Z., Yang, X.-B., Tian, M., Zeng, N., Bai, Z., Deng, W., Zhao, Y., Guo, J.-H., Yang, Y.-C., Zhang, Z.-T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11328-w · Cited by 18
Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review
Alemzadeh, E., Allahqoli, L., Mazidimoradi, A., Alemzadeh, E., Ghasemi, F., Salehiniya, H., & Alkatout, İ. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.031006 · Cited by 19
Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy
Singh, S., Utreja, D., & Kumar, V. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02819-1 · Cited by 17
Mainstreaming genetic counseling for BRCA testing into oncology clinics – Indian perspective
Verma, A. K., Nag, S. M., Hasan, Q. A., & Selvakumar, V. P. P. (2019) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_458_19 · Cited by 17
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines
Choi, P. J., Cooper, E. A., Schweder, P. M., Mee, E. T., Turner, C. P., Faull, R. L. M., Denny, W. A., Dragunow, M., Park, T., & Jose, J. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127252 · Cited by 17
Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma
Sun, G., Miao, G., Li, Z., Zheng, W., Zhou, C., Sun, G., Cao, H., Li, Z., & Tang, W. (2022) · Journal of Oncology · doi:10.1155/2022/6988923 · Cited by 18
Modeling of the Enzyme—Substrate Complexes of Human Poly(ADP-Ribose) Polymerase 1
Nilov, D. K., Pushkarev, S. V., Gushchina, I. V., Manasaryan, G., Игоревич, К. К., & Švedas, V. K. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920010095 · Cited by 17
ATR Inhibitors in Platinum-Resistant Ovarian Cancer
Li, S., Wang, T., Fei, X., & Zhang, M. (2022) · Cancers · doi:10.3390/cancers14235902 · Cited by 16
Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity
Игоревич, К. К., Fetisov, T. I., Antoshina, E. E., Trukhanova, L. S., Gorkova, T. G., Vlasova, O. A., Александровна, Х. И., Lesovaya, E. A., Kulbachevskaya, N. Y., Shcherbakova, T. A., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842316 · Cited by 15
The power and the promise of synthetic lethality for clinical application in cancer treatment
Liu, Q., Yang, Z., Tang, Q.-H., Wang, W.-E., Chu, D.-S., Ji, J.-F., Fan, Q.-Y., Jiang, H., Yang, Q.-X., Zhang, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116288 · Cited by 17
GNAi2/gip2-Regulated Transcriptome and Its Therapeutic Significance in Ovarian Cancer
Ha, J. H., Jayaraman, M., Yan, M., Dhanasekaran, P., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2021) · Biomolecules · doi:10.3390/biom11081211 · Cited by 15
Veliparib: A New Therapeutic Option In Ovarian Cancer?
Ghisoni, E., Giannone, G., Tuninetti, V., Genta, S., Scotto, G., Aglietta, M., Sangiolo, D., Mittica, G., & Valabrega, G. (2019) · Future Oncology · doi:10.2217/fon-2018-0883 · Cited by 15
Self-citation
Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation
Stubbs, F. E., Flynn, B. P., Rivers, C. A., Birnie, M. T., Herman, A., Swinstead, E. E., Baek, S., Fang, H., Temple, J., Carroll, J. S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02516-2 · Cited by 15
m6A ‐related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma
Zhou, X., Zhang, H., Duan, Y., Zhu, J., & Dai, H. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24813 · Cited by 14
The Role of NAD+, SIRTs Interactions in Stimulating and Counteracting Carcinogenesis
Podyacheva, E., & Toropova, Y. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097925 · Cited by 14
The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways
Yin, C., Alqahtani, A. J., & Noel, M. S. (2022) · Cancers · doi:10.3390/cancers14112619 · Cited by 14
Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment
Zhao, D., Long, X., & Wang, J. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s387920 · Cited by 14
PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway
Cao, Q., Li, L., Zhao, Y., Wang, C., Shi, Y., Tao, X., Cai, C., & Han, X. (2023) · Cell Transplantation · doi:10.1177/09636897231187996 · Cited by 13
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Wang, L., Wang, Q., Xu, Y., Cui, M., & Han, L. (2019) · Current Drug Targets · doi:10.2174/1389450120666190925123507 · Cited by 14
Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
Cheng, H., Yang, J., Liu, H., & Xiang, Y. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06070-2 · Cited by 14
CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery
Schleicher, E. M., & Moldovan, G. (2021) · FEBS Journal · doi:10.1111/febs.16217 · Cited by 15
Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study
Zhong, S., Wu, B., Yang, W., Ge, J., Zhang, X., Chen, Z., Duan, H., He, Z., Liu, Y., Wang, H., et al. (2021) · Aging · doi:10.18632/aging.103986 · Cited by 13
ETS transcription factor ELK3 in human cancers: An emerging therapeutic target
Al-Hawary, S. I. S., Pallathadka, H., Hjazi, A. M., Zhumanov, Z. E., Alazbjee, A. A. A., Imad, S., Alsalamy, A., Hussien, B. M., Jafer, N. S., & Mahmoudi, R. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154728 · Cited by 12
Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy
Kelly, T. E., Spillane, C. D., Ward, M. P., Hokamp, K., Huang, Y., Tewari, P., Martin, C. M., Norris, L., Mohamed, B. M., Bates, M., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1150991 · Cited by 12
Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer
Zhang, J., Zheng, H., Gao, Y., Lou, G., Yin, R., Ji, D., Li, W., Wang, W., Xia, B., Wang, D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0565 · Cited by 12
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
Capellero, S., Erriquez, J., Melano, C., Mesiano, G., Genta, S., Pisacane, A. M., Mittica, G., Ghisoni, E., Olivero, M., Renzo, M. F. D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63634-z · Cited by 13
Self-citation
Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers
Ahn, H., Yoon, S. M., Yu, J., Yeom, J., Lee, S., Hur, S. Y., Jung, Y., Kim, K., & Choi, Y. J. (2021) · Cancers · doi:10.3390/cancers13102300 · Cited by 12
Transporter‑mediated drug‑drug interactions involving poly (ADP‑ribose) polymerase inhibitors (Review)
Zhao, D., Long, X., & Wang, J. (2023) · Oncology Letters · doi:10.3892/ol.2023.13747 · Cited by 14
High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders
Peng, X., Li, Y., Qu, J., Jiang, L., Wu, K., Liu, D., Chen, Y., Peng, J., Guo, Y., & Cao, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116405 · Cited by 11
The Effect of Calycosin-7-O-β-D-Glucoside and its Synergistic Augmentation of Cisplatin-induced Apoptosis in SK-OV-3 Cells
Huang, J., Li, L., Tan, X., Wu, Z., Chen, D.-W., & Luo, X. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220610164100 · Cited by 11
Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
Tang, B., Wu, M. Y., Zhang, L., Jian, S., Lv, S., Lin, T., Zhu, S., Liu, L., Wang, Y., Yi, Z., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154073 · Cited by 11
Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review)
Zhao, D., Long, X., & Wang, J. (2021) · Oncology Reports · doi:10.3892/or.2021.8231 · Cited by 12
Precision-Oriented Theophylline-Platinum(IV) Prodrugs: Eliciting Synthetic Lethality in BRCA1-Deficient Ovarian Cancer with Enhanced Efficacy and Reduced Toxicity In Vitro and In Vivo
Liu, X.-M., Zhu, Z., Li, Q., Li, Z., Rong, R., Xie, C., Qiao, X., Feng, Y., & Xu, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01170 · Cited by 10
PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge
Wang, W., Cai, C., Qin, S., He, L., Liang, Q., Siyao, T., Xie, J., Long, T., Hou, J., Kim, W., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01673-8 · Cited by 13
RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)
Kausar, M. A., Alshammari, K. F., Alenazi, F., Anwar, S., Khalifa, A. M., Ginawi, T., Asiri, A., Najm, M. Z., Rabbani, S. A., El‐Tanani, M., et al. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5771 · Cited by 12
Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
Chen, W., Huang, H., Chang, T., & Chou, H. (2020) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2019.10.003 · Cited by 10
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
Le, B. V., Podszywalow‐Bartnicka, P., Piwocka, K., & Skórski, T. (2022) · Cancers · doi:10.3390/cancers14235795 · Cited by 9
Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review
Alaert, J., Lancelle, M., Timmermans, M., Tanos, P., Nisolle, M., & Karampelas, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082282 · Cited by 9
“Resistance to platinum-based chemotherapy may explain the dark outcomes in malignant AWE, but it remains to be determined whether PARPis have a therapeutic place in recurrent malignant AWE [60].”
Background
Targeting TRIP13 for overcoming anticancer drug resistance (Review)
Zhao, L., Ye, S., Jing, S., Gao, Y., & He, T. (2023) · Oncology Reports · doi:10.3892/or.2023.8639 · Cited by 10
Hydrophobic tagging: A promising paradigm for targeted protein degradation
Xin, L., Wang, H., Yang, M., Guo, Z., Zhu, M., Moore, T. W., Dong, C., & Zhou, H. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100295 · Cited by 10
Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response
van den Pol, A. N., Zhang, X., Lima, E., Pitruzzello, M. C., Albayrak, N., Alvero, A. B., Davis, J. N., & Mor, G. (2020) · Virology · doi:10.1016/j.virol.2020.10.009 · Cited by 9
Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types
Zannini, G., Facchini, G., SIO, M. D., Vita, F. D., Ronchi, A., Orditura, M., Vietri, M. T., Ciardiello, F., Franco, R., Accardo, M., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154336 · Cited by 9
VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer
Ning, Y., Zeng, Z., Deng, Y., Feng, W., Huang, L., Liu, H., Lin, J., Zhang, C., Fan, Y., & Liu, L. (2021) · Cancer Science · doi:10.1111/cas.14864 · Cited by 9
Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors
Cao, X., Wu, K., Chen, M., Peng, X., Li, Y., Tang, G., & Peng, J. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220321150700 · Cited by 9
Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors
McMahon, J. T., Faraj, R. R., & Adamson, D. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1836154 · Cited by 8
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review
Chilimoniuk, Z., Rocka, A. A., Stefaniak, M., Tomczyk, Z., Jasielska, F., Madras, D. K., & Filip, A. A. (2022) · Future Oncology · doi:10.2217/fon-2021-0565 · Cited by 8
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
Zitzmann-Kolbe, S., Kristian, A., Zopf, D., Kamfenkel, C., Politz, O., Ellingsen, C., Hilbig, J., Juul, M. U., Fonslet, J., Nielsen, C. H., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0808 · Cited by 7
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
Scotto, G., Borella, F., Turinetto, M., Tuninetti, V., Valsecchi, A. A., Giannone, G., Cosma, S. D., Benedetto, C., & Valabrega, G. (2021) · Cells · doi:10.3390/cells10123408 · Cited by 8
Self-citation
Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches
Li, Z., Li, N., Noah, M. L. N., Shao, Q., & Zhan, X. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00385-1 · Cited by 6
Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification
Li, H., Wu, H., Li, S., Wang, Q., Li, G., Ma, X., Gong, Y., Chu, Y., Jin, S., Chen, X., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112860 · Cited by 6
Olaparib attenuates sepsis-induced acute multiple organ injury via ERK-mediated CD14 expression
Chen, Z., Chen, Y., Jin, X., Liu, Y., Shao, Z., & Li, Q. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211015620 · Cited by 6
Genomic instability in ovarian cancer: Through the lens of single nucleotide polymorphisms
Sistla, H. C., Talluri, S., Rajagopal, T., Venkatabalasubramanian, S., & Dunna, N. R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119992 · Cited by 7
Inhibitory Effects of 7-Methylguanine and Its Metabolite 8-Hydroxy-7-Methylguanine on Human Poly(ADP-Ribose) Polymerase 1
Kurgina, T. A., Shram, S. I., Kutuzov, M. M., Abramova, T. V., Shcherbakova, T. A., Maltseva, E. A., Poroikov, V., Lavrik, O. I., Švedas, V. K., & Nilov, D. K. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922080132 · Cited by 6
Circular RNA hsa_circ_0000144 aggravates ovarian Cancer progression by regulating ELK3 via sponging miR-610
Wu, D., Liu, J., Yu, L., Wu, S., & Qiu, X. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01048-3 · Cited by 6
PARP inhibitor-related haemorrhages: What does the real-world study say?
Wang, S., Guo, M., Zhang, X., Fan, P., & Jin, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1070343 · Cited by 6
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
Tsantikidi, A., Papadopoulou, E., Metaxa-Mariatou, V., Metaxa-Mariatou, V., Kapetsis, G., Florou-Chatzigiannidou, C., Meintani, A., Gazouli, M., PAPADIMITRIOU, C. A., Timotheadou, E. T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13182962 · Cited by 8
Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens
Schossig, P., Coskun, E., Arsenić, R., Horst, D. A., Sehouli, J., Bergmann, E. C., Andresen, N., Sigler, C., Busse, A., Keller, U. B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032292 · Cited by 5
Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H. R., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A., Lænkholm, A., Kruse, T. A., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01655-y · Cited by 5
Computer-aided Drug Discovery Approaches in the Identification of Anticancer Drugs from Natural Products: A Review
Priya, M. G. R., Manisha, J., Lazar, L. P. M., Rathore, S. S. S., & Solomon, V. R. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099283410240406064042 · Cited by 4
Probing the Cytotoxic Signaling Induced by Eupenifeldin in Ovarian Cancer Models
Maldonado, A. C., Haughan, M. A., Khin, M., Ekiert, J., Zhang, Z., Lantvit, D. D., Subeh, Z. Y. A., Pierre, H. C., Salkovski, M., Hirschhorn, T., et al. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00186 · Cited by 4
Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway
Cheng, J., Sun, Y., Zhao, H., Ren, W., Gao, D., Wang, Z., Lv, W., & Dong, Q. (2023) · PeerJ · doi:10.7717/peerj.16314 · Cited by 4
Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis
Knapp, T. M., Nygaard, J., Cassinat, J. J., Galvez, F., & Gopalan, P. K. (2024) · JCO Global Oncology · doi:10.1200/go.23.00379 · Cited by 4
Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
Li, J., Yang, J., & Wang, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1542646 · Cited by 4
Natural Guanine Derivatives Exert PARP-Inhibitory and Cytoprotective Effects in a Model of Cardiomyocyte Damage under Oxidative Stress
Shram, S. I., Shcherbakova, T. A., Abramova, T. V., Baradieva, E. C., Efremova, A. S., Smirnovskaya, M. S., Silnikov, V. N., Švedas, V. K., & Nilov, D. K. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923060068 · Cited by 4
Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials
Mustafa, M. T., Abushanab, A. K., Mousa, M. T., Qawaqzeh, R. A., Alakhras, H. M., Othman, A. S., & Saed, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2309177 · Cited by 4
The Utility of Comprehensive NGS Analysis in Homologous Recombination Deficiency TrackingPreprint
Tsantikidi, A., Papadopoulou, E., Tsaousis, G., Metaxa-Mariatou, V., Kapetsis, G., Florou-Chatzigiannidou, C., Meintani, A., Gazouli, M., PAPADIMITRIOU, C. A., Timotheadou, E. T., et al. (2023) · Preprints.org · doi:10.20944/preprints202307.0781.v1 · Cited by 4

Authors: Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G.
Affiliations: Candiolo Cancer Institute (IT)
Corresponding author: Valabrega, Giorgio
ORCID: Ghisoni, Eleonora
Giannone, Gaia
Genta, Sofia
Aglietta, Massimo
Sapino, Anna
Valabrega, Giorgio
Venue: Recent Patents on Anti-Cancer Drug Discovery
Publisher: Bentham Science Publishers Ltd.
Published: 2018-10-03
Volume: 13
Issue: 4
Pages: 392-410
ISSN: 1574-8928 (ISSN-L)
DOI: 10.2174/1574892813666180305165256
OpenAlex: W2794128499
Cited by: 158
References: 100
Citations by year: 2026: 5 · 2025: 16 · 2024: 21 · 2023: 29 · 2022: 20 · 2021: 27 · 2020: 28 · 2019: 11 · 2018: 1
FWCI: 6.28
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
Locations: Recent Patents on Anti-Cancer Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: PARP inhibitors, epithelial ovarian cancer, recurrent ovarian cancer, olaparib, niraparib, rucaparib, talazoparib, veliparib, BRCA mutations, platinum resistance, secondary resistance, mechanism of action, pharmacokinetics, neoadjuvant therapy, first-line therapy, combination therapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Female, Humans, Ovarian Neoplasms, Phthalazines, Piperazines, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PARP Inhibitors in Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks